M Fatchur Rochman and Isnaeni and Esti Hendradi (2018) Design of Nanostructured Lipid Carriers Ubiquinone-10 for Transdermal Treatment. International Journal of Drug Delivery Technology, 8 (3). pp. 116-120. ISSN 0975 4415

	Text (FULLTEXT (EH)) C-7 fix.pdf Download (4MB)
	Text (SIMILARITY (EH)) Result Bukti C-07.pdf Download (2MB)
	Text (PEER REVIEW (EH)) C-07 Reviewer.pdf Download (1MB)
	Text (FULLTEXT (IS)) C-5b.PDF Download (2MB)
	Text (SIMILARITY (IS)) Hasil turnitin-C--5.pdf Download (2MB)
	Text (PEER REVIEW (IS)) Val C-5.pdf Download (1MB)
	Text (KLARIFIKASI (EH)) C-07 klarifikasi.pdf Download (4MB)

Abstract

Ubiquinone-10 is a cellular endogenous antioxidant that resides in the epidermal layer. Ubiquinone-10 can increase the production of basal membrane components, fibroblast proliferation and protect cells from oxidative damage, so with increasing age, the amount of Ubiquinone-10 body will decrease. Bioavailability and permeability of Ubiquinone-10 are very low, thus affecting the potential efficacy and absorption in Ubiquinone-10. The preparation of Ubiquinone-10 formulation needs to be done to obtain products that have good bioavailability. Nanostructured Lipid Carrier (NLCs) is a modification of the SLN system, consisting of a certain amount of lipid matrix and liquid lipids. Mixtures of solid lipids and liquid lipids can provide space for drug trapping. The system will remain in solid form by controlling the concentration of the liquid lipids to be added into the formula so that the drug release process can be controlled.

Actions (login required)

View Item